NexaphMOTS-c
Ordered MOTS-c from Nexaph? Mail in a sample (US only) and let us test it.
Test my supplyNexaph's strongest purity-focus evidence is in GHK-Cu, with Retatrutide and Tirzepatide improving recently after earlier purity and fill outliers. The record is dispersed: Semaglutide, Tesamorelin, and CJC-1295 remain weak from repeated purity or identity/quantity failures, and batch-ID gaps temper an otherwise current, high-volume dataset.
Corporate records, RDAP data and site emails trace Nexaph through a fragmented operator identity rather than a clean public counterparty. The report maps sister-brand infrastructure, COA-cloning pathways and a certification/payment layer that changes buyer recourse.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Nexaph rows.
Cancel anytime
About Nexaph test results from Finnrick
Nexaph is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 11 peptides and 275 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Nexaph peptides in this dataset are Semaglutide (15 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.
Ordered MOTS-c from Nexaph? Mail in a sample (US only) and let us test it.
Test my supply